Alamar Biosciences
This article was originally published in The Gray Sheet
Executive Summary
Plans an offering of $2.3 mil. in units, each consisting of convertible preferred stock and common stock purchase warrants. Proceeds from the offering are slated for increased marketing efforts for the Sacramento, California-based company's in vitro diagnostic test kits
You may also be interested in...
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
ATAI Raises $125m Series C To Expand The Boundaries In Mental Health
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: